DENVER–(BUSINESS WIRE)–Indication BioScience, a clinical-stage biopharmaceutical company developing next-generation combination therapies for cardiometabolic disease, today announced encouraging early findings from its ongoing Phase I study of Atorvo+™. The investigational therapy combines atorvastatin — the world’s most prescribed cholesterol-lowering statin — with a proprietary orally active solid form of cannabidiol. Atorvo+™ is being developed as a first-line statin therapy, designed to i